Evidence map›Paper›PMID 34781951›Full record

ArticleBMC medicine2021

COVID-19 and risk of subsequent life-threatening secondary infections: a matched cohort study in UK Biobank.

Can Hou, Yihan Hu, Huazhen Yang, Wenwen Chen, Yu Zeng, Zhiye Ying, Yao Hu, Yajing Sun, Yuanyuan Qu, Magnús Gottfreðsson and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Can HouWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Yihan HuWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Huazhen YangWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Wenwen ChenDivision of Nephrology, Kidney Research Institute, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
Yu ZengWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Zhiye YingWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Yao HuWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Yajing SunWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Yuanyuan QuWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China.
Magnús GottfreðssonDepartment of Internal Medicine, Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavík, Iceland.
Unnur A ValdimarsdóttirCenter of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland.
Huan SongWest China Biomedical Big Data Center, West China Hospital, Sichuan University, Guo Xue Lane 37#, Chengdu, 610041, China. songhuan@wchscu.cn.
West China Medical Center of Sichuan University · CNSichuan University · CNUniversity of Iceland · ISState Key Laboratory of Biotherapy

Funding

1.3.5 project for disciplines of excellence, west china hospital, sichuan university ZYYC21005Medical Research Council MC_PC_17228Medical Research Council MC_QA137853national natural science foundation of china 81971262nordforsk grant 105668
6 · The paper itself

Abstract

backgroundWith the increasing number of people infected with and recovered from coronavirus disease 2019 (COVID-19), the extent of major health consequences of COVID-19 is unclear, including risks of severe secondary infections.

methodsBased on 445,845 UK Biobank participants registered in England, we conducted a matched cohort study where 5151 individuals with a positive test result or hospitalized with a diagnosis of COVID-19 were included in the exposed group. We then randomly selected up to 10 matched individuals without COVID-19 diagnosis for each exposed individual (n = 51,402). The life-threatening secondary infections were defined as diagnoses of severe secondary infections with high mortality rates (i.e., sepsis, endocarditis, and central nervous system infections) from the UK Biobank inpatient hospital data, or deaths from these infections from mortality data. The follow-up period was limited to 3 months after the initial COVID-19 diagnosis. Using a similar study design, we additionally constructed a matched cohort where exposed individuals were diagnosed with seasonal influenza from either inpatient hospital or primary care data between 2010 and 2019 (6169 exposed and 61,555 unexposed individuals). After controlling for multiple confounders, Cox models were used to estimate hazard ratios (HRs) of life-threatening secondary infections after COVID-19 or seasonal influenza.

resultsIn the matched cohort for COVID-19, 50.22% of participants were male, and the median age at the index date was 66 years. During a median follow-up of 12.71 weeks, the incidence rate of life-threatening secondary infections was 2.23 (123/55.15) and 0.25 (151/600.55) per 1000 person-weeks for all patients with COVID-19 and their matched individuals, respectively, which corresponded to a fully adjusted HR of 8.19 (95% confidence interval [CI] 6.33-10.59). The corresponding HR of life-threatening secondary infections among all patients with seasonal influenza diagnosis was 4.50, 95% CI 3.34-6.08 (p for difference < 0.01). Also, elevated HRs were observed among hospitalized individuals for life-threatening secondary infections following hospital discharge, both in the COVID-19 (HR = 6.28 [95% CI 4.05-9.75]) and seasonal influenza (6.01 [95% CI 3.53-10.26], p for difference = 0.902) cohorts.

conclusionCOVID-19 patients have increased subsequent risks of life-threatening secondary infections, to an equal extent or beyond risk elevations observed for patients with seasonal influenza.

Indexed as

CoinfectionCOVID-19Biological Specimen BanksCohort StudiesCOVID-19 TestingHumansMaleSARS-CoV-2United KingdomCOVID-19Life-threatening infectionsSepsisSevere secondary infections

Identifiers

PMID34781951
PMCPMC8592806
OpenAlexW3211453866

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.